A class action lawsuit has been filed against Baxter International Inc. on behalf of investors who suffered losses due to alleged securities fraud between February 23, 2022 and July 30, 2025. The complaint claims that Baxter made false or misleading statements regarding its Novum LVP product, which reportedly suffered from systemic defects causing underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients. It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths but failed to take adequate remedial action, while continuing to make positive statements about the product's safety and sales prospects. The lawsuit seeks to recover damages for affected shareholders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1114349) on December 03, 2025, and is solely responsible for the information contained therein.